摘要
弥漫性大B细胞淋巴瘤(DLBCL)是一种侵袭性B细胞淋巴瘤,尽管R-CHOP(利妥昔单抗+环磷酰胺+阿霉素+长春新碱+泼尼松)方案的使用已明显改善患者预后,但仍有部分患者在治疗后复发或发展为难治性疾病。近年来,在详细的遗传信息的指导下,除了传统药物及干细胞移植等疗法外,针对免疫检查点、肿瘤微环境、分子信号传导途径和表观遗传突变的治疗药物以及细胞免疫疗法等构成了治疗复发/难治性DLBCL的新局面,为促进DLBCL患者的精准医学治疗提供了新的途径。本文就复发/难治性DLBCL的治疗进展进行综述。
Diffuse large B-cell lymphoma(DLBCL)is a highly invasive B-cell lymphoma.Although the use of R-CHOP(rituximab,cyclophosphamide,adriamycin,vincristine and prednisone)regimen has significantly improved the prognosis of patients,some patients still relapse or develop into refractory diseases after treatment.In recent years,under the guidance of detailed genetic information,in addition to traditional drugs and stem cell transplantation,therapeutic drugs for immune checkpoints,tumor microenvironment,molecular signal transduction pathway and epigenetic mutation and cellular immunotherapy constitute a new situation for the treatment of recurrent/refractory DLBCL.It provides a new way to promote the precision medical treatment of DLBCL patients.This paper reviews the treatment progress of recurrent/refractory DLBCL.
作者
齐瑞丽
邱鸣寒
张廷
赵轩竹
何国平
梅汉玮
王华庆
QI Ruili;QIU Minghan;ZHANG Ting;ZHAO Xuanzhu;HE Guoping;MEI Hanwei;WANG Huaqing(Department of Oncology,the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)
出处
《临床肿瘤学杂志》
CAS
2022年第8期758-763,共6页
Chinese Clinical Oncology
基金
国家自然科学基金面上项目(82070206)
河南省卫生健康委国家中医临床研究基地科研专项(2022JDZX130)
天津市人民医院院内项目(2019YJ006)。
关键词
弥漫大B细胞淋巴瘤
复发/难治
靶向治疗
免疫治疗
移植
Diffuse large B-cell lymphoma
Relapse/refractory
Targeted therapy
Immunotherapy
Transplant
